Europe (UK): +44 1732 316319 | India: +91 20 71531039 | USA: +1 855 2596535

WEB DEMO
  • Home
  • About
    • Our Story
    • The Executive Team
    • Why CRFWEB?
    • Contact
      • Our locations
      • Europe – UK Office
      • India
    • Careers
    • Security and compliance
  • Solutions
    • The EDC process
    • eCRF
    • MedDRA
    • Randomization
    • ePRO
    • eDiary
    • The Clindox App
    • Clindox eLab
    • Innovations Hub
  • Medical Devices
    • Medical Devices Home
    • Introduction to Medical Device Investigations
    • Pre-Licence Investigations
    • Post-Market Investigations
    • Technologies for Investigations
      • technologies for medical device clinical trials
      • ePRO & eDiary for medical device clinical trials
      • EDC for medical device clinical trials
      • The Clindox App for medical devices
      • Clindox eLab
    • Medical Device Regulations
    • Medical Device Resource Centre
    • Clindox for IVD Studies
  • Other Sectors
    • Pharma-Biotech
    • Nutraceuticals
    • CROs
    • Academia
    • Clindox for IVD Studies
  • News
WEB DEMO
  • Home
  • About
    • Our Story
    • The Executive Team
    • Why CRFWEB?
    • Contact
      • Our locations
      • Europe – UK Office
      • India
    • Careers
    • Security and compliance
  • Solutions
    • The EDC process
    • eCRF
    • MedDRA
    • Randomization
    • ePRO
    • eDiary
    • The Clindox App
    • Clindox eLab
    • Innovations Hub
  • Medical Devices
    • Medical Devices Home
    • Introduction to Medical Device Investigations
    • Pre-Licence Investigations
    • Post-Market Investigations
    • Technologies for Investigations
      • technologies for medical device clinical trials
      • ePRO & eDiary for medical device clinical trials
      • EDC for medical device clinical trials
      • The Clindox App for medical devices
      • Clindox eLab
    • Medical Device Regulations
    • Medical Device Resource Centre
    • Clindox for IVD Studies
  • Other Sectors
    • Pharma-Biotech
    • Nutraceuticals
    • CROs
    • Academia
    • Clindox for IVD Studies
  • News

CRFWEB INFO SHEET

PMCF Activities – A Deeper Dive

PMCF Activities – a deeper dive

The aim of any PMCF activity is to produce a dataset that demonstrates scientifically both the safety and clinical performance of a device. The expectation is that under MDR, very many more PMCF Studies will need to be performed than has been the case to date under MDD, but there are other PMCF activities that may well be valid alternatives depending on the outcome of your MDR Gap Analysis.

MDR Gap Analysis

A manufacturer will need to undertake a systematic review of all data relating to the safety and performance of the device in question to identify where the evidence base fails to meet MDR requirements. It goes without saying that a thorough and accurate assessment of these “evidence gaps” is the very first step toward developing a comprehensive MDR compliance strategy.  The manufacturer will need to ensure that the device achieves conformity with all relevant MDR Annex I General Safety and Performance Requirements (GSPRs). These replace the Essential Requirements of MDD and are far more demanding; an evidence base that provided conformity with MDD may no longer be sufficient for MDR. The Gap Analysis must also identify what type of PMS and PMCF activities are needed to conform with MDR.

Naturally, many SMEs – most of the medical device sector – will only benefit from getting specialist regulatory and clinical affairs advice to perform a Gap Analysis and develop MDR-compliant mitigation strategies.

PMCF activity planning – the diminished role of equivalence

Claiming equivalence with existing devices is far tougher under MDR. The regulations specify that “…it shall be clearly demonstrated that manufacturers have sufficient levels of access to the data relating to devices with which they are claiming equivalence in order to justify their claims of equivalence”. This will be very challenging for many manufacturers and may not be possible at all for some devices.  The Notified Body will assess the validity of equivalence claims – and their assessment may subject to the scrutiny of an EU expert panel. The attraction then of undertaking specific PMCF activities is that a manufacturer will usually have direct access to the data.

PMCF activity planning – other considerations

There are other issues that need to be considered when deciding on what sort of PMCF activities are included in the MDR compliance strategy, principally:

  • Medical Device classification
  • Number of devices in use
  • Access to customers/end-users and access to patients
  • Clinical or industry measure standards for Device performance
  • Real word device use
  • Existing data sources – and the availability of consent

Medical Device classification

The Periodic Safety Update Report (PSUR – article 86 of MDR) is a new MDR reporting requirement for all device classes, except class I.  PSURs are required at least every year for class III devices and class IIb implantables and at least every two years for class IIa devices and class IIb non-implantables. PSUR is based on PMCF, and so for the most part, PMCF would be required for these classes of device. According to MDR, some devices may not require PMCF, but there is no hard and fast guidance around what constitutes solid grounds for exemption. The Notified Body will assess requests for exemption, which in turn may be referred to an EU expert panel. The amount of time available to produce sufficient data the first PMCF report will be a key consideration when it comes to deciding on what type of PMCF activity is chosen.

Numbers of devices in use

If only low numbers of devices are in use, it may not be possible to run observational activities that will generate sufficient data to be statistically robust and MDR-compliant. In such cases, it may be necessary to initiate an interventional study.

Access to customers/end-users and access to patients

Do you have sufficiently strong relationships with your local health economy customers and/or clinical end-users enabling you to gather feedback and further information about your device? Would you be able to approach clinical end-users directly to discuss some sort of collaboration or do the local distributors effectively own these relationships and are unable to share that information? Without these relationships in place, it will be very difficult to instigate PMCF surveys.

Do you have consent to access patient data, or have the permissions and means in place to contact patients directly to gather patient-reported outcomes or other feedback? It’s vital for compliance to have prior, valid data processing consents in place. Similarly, if the intention is to make use of a public registry for PMCF purposes, you will need to that patients have provided consent to process their data.

Clinical or industry measure standards for Device performance

Most devices will have accepted industry standard measures for performance and safety that define what data should be gathered – and from whom. Some PMCF activities might not provide data to this standard and will therefore need to be exempt from consideration.

What data is required and from whom? Some activities might not fit your device, because the data originating from that activity might not suffice the standard required to document performance.

Real world device use

If a device always needs the intervention, oversight or control of a clinician when in use, it might not be possible work with patients directly to generate compliant data for PMCF surveys or studies.

Existing data sources – and the availability of consent

It’s important to ensure that you have consents in place to be able to access existing registries or other data sources that contain relevant data for PMCF.

Overview of all main PMCF Activities

Common PMCF activities include:

  • PMCF Surveys
  • PMCF Studies and Investigations
  • Registries
  • Investigator Initiated Trial or Investigator Initiated Studies
  • PMCF Cohort Surveys
  • PMCF Case Series
  • Literature searches

The activity or activities most appropriate to meet your PMCF requirements will depend on the outcome of your Gap Analysis and the other considerations outlined above. Below is quick look at the benefits and drawbacks of each of these activities; this is not an exhaustive list; there may well be others you’ll need to consider.

PMCF Surveys

PMCF Surveys are fast becoming one of the most popular tools in the medical device sector for gathering PMCF data. Surveys can be designed for both patients and clinicians.

PMCF Surveys – the Benefits

Surveys are generally resource light – certainly when compared with a clinical investigation or Investigator Initiated Study.  Assuming the company has access to patients or clinicians who deploy the device in their practice, it can be straightforward to initiate a survey asking validated questions on performance and/or safety. In many countries such surveys do not need approvals from ethics committees – although this is governed on a country-by-country basis. Survey participation does not need to be onerous and, assuming ethics approval is not required, surveys can be a quick and relatively inexpensive way of gathering PMCF-compliant data.

PMCF Surveys – the Drawbacks

Surveys require access to sufficient end-users (patients or clinicians) to provide a statistically valid sample of the total population using the device. As devices are often sold through distributors who cannot provide any end-user information, the possibility of conducting a survey may simply be a non-starter for this reason alone.

Where access to patients is available, surveying them concerning performance and safety of certain types of devices might not provide relevant or compliant data – surveying the clinician is required and that has its own drawbacks.  It might be, for example, that the clinician does not know the exact make and model of device used and so questions will have to be necessarily generic. Even where this information is available, it can be hard to develop a questionnaire that is not skewed by a subjective assessment of performance.  In such circumstances surveys may not be able to yield valid data for PMCF purposes.

PMCF Studies and Investigations (Including PMCF Registries)

PMCF studies or post-market investigations (both observational and interventional) remain very popular for PMCF. The design of the study or investigation will depend on the nature of the device (risk class is very important here) and other factors as described above such as number of devices actually in use and what prior gap analysis has revealed as important uncertainties that need to be resolved.  These can be either of observational or interventional, but of course, interventional studies or investigations will require far more planning and more detailed documentation to meet regulatory obligations.

Where sufficient devices are in use, Manufacturers can initiate observational investigations – also known as PMCF registries.

PMCF Studies and Investigations – the Benefits

A properly designed and executed PMCF study or investigation will pretty much ensure that the data quality will be acceptable to the Notified Body. Also, you will have control of exactly what data is collected – and how it might be used.

PMCF Studies and Investigations – the Drawbacks

Studies and investigations will be more expensive and resource intensive when compared with most other options. The data quality and control come at a cost of additional resources.  Some devices will need to be followed-up over several years and so may be that there will be insufficient data on performance and safety to be used for PMCF purposes for a long time and so PMCF reports will need to supported with other activities in the short to medium term.

Registries

Registries are databases established and maintained by governmental/public or private bodies and can contain valuable information on the usage and clinical outcomes of medical devices in the real world. They tend to be widespread for Class III and other long-term implantable devices, and commonly contain detailed information on cases. Registries do exist for devices of lower risk-class, but are far less common and may not be easily accessed by manufacturers as they have only been established for research purposes.

Registries – the Benefits

There is an evident cost saving if a new study does not have been initiated to collect the data, providing the third-party registry has collected data on the device in question with a sufficient level of traceability and detail needed to meet the needs of PMCF.

Registries – the Drawbacks

There’s no guarantee that a registry will exist for a device – or in every country where the device is in use.  The quality, value and usefulness for PMCF of the data can vary hugely from one country to another.

Another thorny issue in Europe is GDPR. Data processing consents – where they exist – might be insufficient to allow manufacturers to access the data.

Investigator Initiated Studies and Trials (IIS)

Investigator initiated studies (IIS) are clinical studies initiated and managed by a non-pharmaceutical company researchers, like individual investigators, institutions, collaborative study groups or cooperative groups. Manufacturers may support investigator-initiated studies with drug supply, funding, material and/or information, as allowed under local laws and regulations, provided that they align with the company defined areas of strategic interest.

IIS – the Benefits

From the perspective of PMCF, this independence – providing the study or trial are fit-for-purpose – will be obviously beneficial as a source of legitimate PMCF. A significant proportion of the overall cost may remain the responsibility of the Investigator and so there is also the attraction of cost-saving.

IIS – the Drawbacks

The devil is in the detail; not having direct authority for ensuring that the correct standards (e.g., ISO 14155:2020) are adhered to can be a real problem. If they are not, then the study will not be MDR-compliant. There will be a cost, usually born by the manufacturer, to mitigate problems caused by any failure to ensure that these standards are met. Also, as the investigator is running the show, it might actually be difficult to ensure that the data collected is sufficiently relevant for PMCF.

PMCF Cohort studies

These are a type of longitudinal study—an approach that follows research participants over a period of time (often many years). Specifically, cohort studies recruit and follow participants who share a common characteristic, such as a particular occupation or demographic similarity.

PMCF Cohort Studies – the Benefits

Surveys are generally resource light – certainly when compared with a clinical investigation or Investigator Initiated Study.  Assuming the company has access to patients or clinicians who deploy the device in their practice, it can be straightforward to initiate a survey asking validated questions on performance and/or safety. In many countries such surveys do not need approvals from ethics committees – although this is governed on a country-by-country basis. Survey participation does not need to be onerous and, assuming ethics approval is not required, surveys can be a quick and relatively inexpensive way of gathering PMCF-compliant data. The gold-standard of this type of study is to be able to commence data gathering before a device is deployed in the cohort, as well as after. This provides more robust evidence on both safety and performance, when compared with simple retrospective data gathering.

PMCF Cohort Studies – the Drawbacks

Surveys require access to sufficient end-users (patients or clinicians) to provide a statistically valid sample of the total population using the device. As devices are often sold through distributors who cannot provide any end-user information, the possibility of conducting a survey may simply be a non-starter for this reason alone.

Where access to patients is not available, surveying the clinician would be necessary, but that has its own drawbacks.  For example, the clinician may not know the exact make and model of device used and so questions will have to be necessarily generic. Even where this information is available, it can be hard to develop a questionnaire that is not skewed by a subjective assessment of performance.  In such circumstances surveys may not be able to yield valid data for PMCF purposes.

PMCF Case Series

A case study, also known as a case report, is an in depth or intensive study of a single individual or specific group, while a case series is a grouping of similar such case studies / case reports together.

PMCF Case Series – the Benefits

Manufacturers and their representatives have long gathered basic case study data from clinicians to record and assess the safety and efficacy of devices. In the past, this has often been a paper-based activity with all the hassle that can bring, but the availability of eclinical solutions promises to streamline this process, making it fit for PMCF.

PMCF Case Series – the Drawbacks

For devices in the higher risk classes, it’s not easy to initiate a case series where long-term follow-up on detailed clinical outcomes is required.  They are more effective for studies where the dataset is comparatively simple and data collection is required over a relatively short period of time. Naturally, Case Series will require good relationships with physicians and other key opinion leaders, who will need to be incentivised to drive continued data collection.

Literature searches

MDR does not specifically exclude the use of references to published literature that have valid and relevant information concerning the safety and efficacy of devices; these can continue to be used in support of PMCF.

Literature searches – the Pros

Straightforward and low-cost. In the past, this has been a major source of PMCF – particularly for devices that belong to product families for which there is a huge amount of information available on safety and performance in the literature.

Literature searches – the Cons

EU MDR Annex XIV makes it clear that if equivalence claims are to be presented to support claims made about safety and efficacy, then the manufacturer must have “sufficient levels of access to the data relating to devices with which they are claiming equivalence in order to justify their claims of equivalence.” This stipulation explicitly includes PMCF.

There will be no guarantees that a manufacturer will be able to secure access to the underlying data referenced in the literature. Any claims to equivalence without that access will be inadmissible.

For further information concerning PMCF follow the links below:

  • PMS & PMCF under MDR – an Overview
  • PMCF Planning – an Overview
  • PMCF Studies – an Overview

How can we help you?

With the advent of MDR, it’s harder than ever to argue that NOT investing in EDC makes sense.

CRFweb is a full-service EDC system optimized for medical devices. CRFweb will support your journey to compliance providing a single, integrated platform for:

  • Clinical trial design
  • Data capture by site or subject
  • Trial process management and troubleshooting
  • Data management, analysis and reporting

The CRFweb software suite delivers all the key functionality you will need to ensure an MDR-compliant clinical trial in an agile, simple-to-use package optimised for the needs of medical devices at a fraction of the cost of the industry big names.

Contact us today to book your demo

5 Star Reviewed

5 Star rated on Capterra

What our clients say

Maria Galligan, PMD Solutions

" The Clindox team have been an incredible support and are always available to help in any way they can."

Dr Salvi, CRF Health, India

" The time and cost saving is really significant. We're very happy with the performance or CRFweb and I wouldn't hesitate to recommend it."

Nigel McLean, Cytosystems, UK

" CRFWEB eCRF, plus their helpful and accommodating staff, helped us quickly set up and personalize, with quick turn-around times of modifications, exactly what we, the clinical staff, and statistical consultants demanded, all at an affordable price "

Kelly Seamans, Atlantia

" The Clindox (CRFWEB) team are dedicated and enthusiastic about accommodating the unique requirements of each individual study and are great value for money."

Dr Satish Kumar, G7 Synergon
"Our international CRO business has utilized Clindox's integrated randomization module and Kit Management. The functionality provides everything we need, and having key trial components integrated into one system is a huge advantage to us in terms of trial efficiencies. Having both randomization and kit management capabilities, aligned with the EDC really simplifies the whole process and significantly reduces the time and effort required to manage our studies and keep control of our processes and inventory. "

Next Steps

For a quick system overview, click here

Seeing is believing. Book a web-based demo now.

Book a demo

Useful Links

  • eCRF
  • eDIARY
  • ePRO
  • MedDRA
  • Randomization
  • Security and compliance

Latest News

June 20, 2022

Meeting the IVDR challenge: digitizing the collection of study data

Read more
March 14, 2022

Covid-19: What has been the impact of the pandemic on India and how have Indian Clinical Trials been affected?

Read more
January 18, 2022

Decentralized Clinical Trials – new kid on the block or a venerable idea resurrected?

Read more

5 Star rated on Capterra

CRFWEB is a clinical trial software application by Clindox

Clindox-8-300x212

Policies

Privacy Policy
Security policy

UK

+44 1732 316319

India

+91 207 1531039

Social Links

Facebook Twitter Linkedin

Registered number: 526690 © Copyright CRFweb 2019

Web design Yorkshire by Feel Design